Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

177Lu-DOTATATE

  • Impact of Single-Time-Point Estimates of <sup>177</sup>Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles
    You have access
    Impact of Single-Time-Point Estimates of 177Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles
    Alexandre Chicheportiche, Moshe Sason, Mahmoud Zidan, Jeremy Godefroy, Yodphat Krausz, David J. Gross, Simona Grozinsky-Glasberg and Simona Ben-Haim
    Journal of Nuclear Medicine July 27, 2023, jnumed.122.264923; DOI: https://doi.org/10.2967/jnumed.122.264923
  • You have access
    Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic
    Michael C. Bellavia, Ravi B. Patel and Carolyn J. Anderson
    Journal of Nuclear Medicine November 1, 2022, 63 (11) 1636-1641; DOI: https://doi.org/10.2967/jnumed.122.264373
  • Safety of Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE in Neuroendocrine Tumor Patients with Chronic Kidney Disease
    You have access
    Safety of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients with Chronic Kidney Disease
    Shahad Alsadik, Gopinath Gnanasegaran, Luohai Chen, Dalvinder Mandair, Christos Toumpanakis, Martyn Caplin and Shaunak Navalkissoor
    Journal of Nuclear Medicine October 1, 2022, 63 (10) 1503-1508; DOI: https://doi.org/10.2967/jnumed.121.263056
  • Modeling Early Radiation DNA Damage Occurring During <sup>177</sup>Lu-DOTATATE Radionuclide Therapy
    Open Access
    Modeling Early Radiation DNA Damage Occurring During 177Lu-DOTATATE Radionuclide Therapy
    Giulia Tamborino, Yann Perrot, Marijke De Saint-Hubert, Lara Struelens, Julie Nonnekens, Marion De Jong, Mark W. Konijnenberg and Carmen Villagrasa
    Journal of Nuclear Medicine May 1, 2022, 63 (5) 761-769; DOI: https://doi.org/10.2967/jnumed.121.262610
  • 
    Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with <sup>177</sup>Lu-DOTATATE
    You have access
    Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with 177Lu-DOTATATE
    Daniel Roth, Johan Gustafsson, Carl Fredrik Warfvinge, Anna Sundlöv, Anna Åkesson, Jan Tennvall and Katarina Sjögreen Gleisner
    Journal of Nuclear Medicine March 1, 2022, 63 (3) 399-405; DOI: https://doi.org/10.2967/jnumed.121.262069
  • Dosimetric Evaluation of the Effect of Receptor Heterogeneity on the Therapeutic Efficacy of Peptide Receptor Radionuclide Therapy: Correlation with DNA Damage Induction and In Vivo Survival
    Open Access
    Dosimetric Evaluation of the Effect of Receptor Heterogeneity on the Therapeutic Efficacy of Peptide Receptor Radionuclide Therapy: Correlation with DNA Damage Induction and In Vivo Survival
    Giulia Tamborino, Julie Nonnekens, Marijke De Saint-Hubert, Lara Struelens, Danny Feijtel, Marion de Jong and Mark W. Konijnenberg
    Journal of Nuclear Medicine January 1, 2022, 63 (1) 100-107; DOI: https://doi.org/10.2967/jnumed.121.262122
  • A Novel Time–Activity Information-Sharing Approach Using Nonlinear Mixed Models for Patient-Specific Dosimetry with Reduced Imaging Time Points: Application in SPECT/CT After <sup>177</sup>Lu-DOTATATE
    You have access
    A Novel Time–Activity Information-Sharing Approach Using Nonlinear Mixed Models for Patient-Specific Dosimetry with Reduced Imaging Time Points: Application in SPECT/CT After 177Lu-DOTATATE
    Theresa P. Devasia, Yuni K. Dewaraja, Kirk A. Frey, Ka Kit Wong and Matthew J. Schipper
    Journal of Nuclear Medicine August 1, 2021, 62 (8) 1118-1125; DOI: https://doi.org/10.2967/jnumed.120.256255
  • You have access
    A Rapid and Safe Infusion Protocol for 177Lu Peptide Receptor Radionuclide Therapy
    Sander C. Ebbers, Maarten W. Barentsz, Bart de Keizer, Gerard C. Krijger, Marnix G.E.H. Lam and Arthur J.A.T. Braat
    Journal of Nuclear Medicine June 1, 2021, 62 (6) 816-822; DOI: https://doi.org/10.2967/jnumed.120.252494
  • You have access
    Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy
    Jonathan R. Strosberg, Taymeyah Al-Toubah, Eleonora Pellè, Johnna Smith, Mintallah Haider, Tai Hutchinson, Jason B. Fleming and Ghassan El-Haddad
    Journal of Nuclear Medicine January 1, 2021, 62 (1) 69-72; DOI: https://doi.org/10.2967/jnumed.120.242875
  • You have access
    Effect of Tumor Perfusion and Receptor Density on Tumor Control Probability in 177Lu-DOTATATE Therapy: An In Silico Analysis for Standard and Optimized Treatment
    Luis David Jiménez-Franco, Gerhard Glatting, Vikas Prasad, Wolfgang A. Weber, Ambros J. Beer and Peter Kletting
    Journal of Nuclear Medicine January 1, 2021, 62 (1) 92-98; DOI: https://doi.org/10.2967/jnumed.120.245068

Pages

  • Next
  • 1
  • 2
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire